Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · see citing works

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075 · see citing works

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659 · see citing works

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Paik, S., Tang, G., Shak, S., Kim, C., Baker, J. B., Kim, W., Cronin, M. T., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,576 · see citing works

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397 · see citing works

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · see citing works

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,054 · see citing works

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor–positive breast cancer: ATLAS, a randomised trial

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044 · see citing works

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Cardoso, F., Veer, L. J. V., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J., Brain, E. G. C., Causeret, S., Delorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,998 · see citing works

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Pan, H., Gray, R. G., Braybrooke, J. P., Davies, C., Taylor, C. W., McGale, P., Peto, R., Pritchard, K. I., Bergh, J. C. S., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,834 · see citing works

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574 · see citing works

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,523 · see citing works

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,518 · see citing works

Gene-Expression Signatures in Breast Cancer

Sotiriou, C. P., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,482 · see citing works

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276 · see citing works

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,252 · see citing works

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martín, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,056 · see citing works

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001 · see citing works

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991 · see citing works

Breast-Cancer Risk in Families with Mutations in PALB2

Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., Leeneer, K. D., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 853 · see citing works

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A. I., Blohmer, J., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774 · see citing works

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

Bergh, J. C. S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60908-4 · Cited by 754 · see citing works

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

Cuzick, J. M., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L. A., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 741 · see citing works

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

Dowsett, M., Cuzick, J. M., Wale, C., Forbes, J., Mallon, E., Salter, J., Quinn, E., Dunbier, A. K., Baum, M., Buzdar, A. U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724 · see citing works

Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722 · see citing works

Genomic characterization of metastatic breast cancers

Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N. M., Piscuoglio, S., Carbuccia, N., Soria, J., Dien, A. T., Adnani, Y., Kamal, M. T., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 715 · see citing works

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 691 · see citing works

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674 · see citing works

Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less

Fisher, B., Bryant, J., Dignam, J. J., Wickerham, D. L., Mamounas, E. P., Fisher, E. R., Margolese, R. G., Nesbitt, L., Paik, S., Pisansky, T. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.101 · Cited by 668 · see citing works

Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Ellis, M. J., Tao, Y., Luo, J. R., A’Hern, R., Evans, D. B., Bhatnagar, A. S., Ross, H. A. C., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 654 · see citing works

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H. B., Gralow, J. R., Gelmon, K. A., Whelan, T. J., Strasser‐Weippl, K., Rubin, S. H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 647 · see citing works

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., Watson, D., Geyer, C. E., Wickerham, D. L., & Wolmark, N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7610 · Cited by 617 · see citing works

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M. V., Panasci, L., Manikhas, A., Shparyk, Y. V., Cardona‐Huerta, S., Cheung, K., Philco, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 583 · see citing works

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904819 · Cited by 535 · see citing works

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

Spring, L. M., Wander, S. A., André, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 482 · see citing works

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival

Partridge, A. H., Hughes, M. E., Warner, E. T., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8013 · Cited by 478 · see citing works

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 443 · see citing works

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

Ades, F., Zardavas, D., Božović‐Spasojević, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C. P., & Piccart, M. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 441 · see citing works

A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes

Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G. S., Kidd, J., Brown, K. L., Sharma, L., Saam, J. R., Lancaster, J. M., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 400 · see citing works

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1897 · Cited by 396 · see citing works

Breast Cancer in Men

Giordano, S. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1707939 · Cited by 392 · see citing works

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

Clark, G. M., Osborne, C. K., & McGuire, W. L. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.10.1102 · Cited by 391 · see citing works

Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

Henry, N. L., Azzouz, F., Desta, Z., Li, L., Nguyen, A., Lemler, S. M., Hayden, J. A., Tarpinian, K., Yakim, E., Flockhart, D. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0261 · Cited by 385 · see citing works

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

Barroso‐Sousa, R., Jain, E., Cohen, O., Kim, D., Buendia-Buendia, J. E., Winer, E. P., Lin, N., Tolaney, S. M., & Wagle, N. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.010 · Cited by 363 · see citing works

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Tung, N., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A. J., Balmañà, J., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 334 · see citing works

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Swain, S. M., Jeong, J., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J. A., Vogel, V. G., Erban, J. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909638 · Cited by 331 · see citing works

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Küemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 325 · see citing works

Genomic Characterization of Primary Invasive Lobular Breast Cancer

Desmedt, C., Zoppoli, G. M., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D. N., Rothé, F., Vincent, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0334 · Cited by 320 · see citing works

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

Šestak, I., Buus, R., Cuzick, J. M., Dubsky, P. C., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D. C., Schnabel, C. A., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 320 · see citing works

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic‐Radisic, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312 · see citing works

Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O’Shaughnessy, J., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294 · see citing works

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288 · see citing works

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244 · see citing works

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Ferreira, A. R., Meglio, A. D., Pistilli, B., Gbenou, A. S., Mouhebb, M. E., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz298 · Cited by 231 · see citing works

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Alba, E., Calvo, L., Albanell, J., de la Haba-Rodríguez, J., Lanza, A. A., Chacón, J. I., Sánchez‐Rovira, P., Plazaola, A., García‐Asenjo, J. A. L., Bermejo, B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds132 · Cited by 229 · see citing works

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 228 · see citing works

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

Šestak, I., Dowsett, M., Zabaglo, L. A., López‐Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt244 · Cited by 221 · see citing works

BRCA1/2 testing: therapeutic implications for breast cancer management

Tung, N., & Garber, J. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0127-5 · Cited by 220 · see citing works

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

Bartlett, J. M. S., Bayani, J., Marshall, A., Dunn, J., Campbell, A. M., Cunningham, C., Sobol, M. S., Hall, P. S., Poole, C. J., Cameron, D., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw050 · Cited by 216 · see citing works

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Blok, E. J., Kroep, J. R., Kranenbarg, E. M., Carpentier, M. D., Putter, H., Bosch, J., Maartense, E., van Leeuwen‐Stok, A. E., Liefers, G., Nortier, J. W. R., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 202 · see citing works

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

Metzger, O., Giobbie‐Hurder, A., Mallon, E., Gusterson, B. A., Viale, G., Winer, E. P., Thurlimann, B. J. K., Gelber, R. D., Colleoni, M. A., Ejlertsen, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8133 · Cited by 188 · see citing works

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Bernhard, J., Luo, W., Ribi, K., Colleoni, M. A., Burstein, H. J., Tondini, C. A., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00049-2 · Cited by 178 · see citing works

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F., Lévy, C., Mouret‐Reynier, M., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 174 · see citing works

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Fribbens, C. V., García-Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 168 · see citing works

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., Chia, S., Brufsky, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30621-1 · Cited by 168 · see citing works

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Turner, N. C., Swift, C., Kilburn, L., Fribbens, C. V., Beaney, M., García-Murillas, I., Budzar, A. U., Robertson, J. F. R., Gradishar, W. J., Piccart, M. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0224 · Cited by 164 · see citing works

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial

Melisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155 · see citing works

Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer

Li, Y., Yang, D., Yin, X., Zhang, X., Huang, J., Wu, Y., Wang, M., Yi, Z., Li, H., Li, H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18160 · Cited by 152 · see citing works

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Kalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 152 · see citing works

Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group

Tevaarwerk, A. J., Wang, Μ., Zhao, F., Fetting, J. H., Cella, D. F., Wagner, L. I., Martino, S., Ingle, J. N., Sparano, J. A., Solin, L. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6993 · Cited by 147 · see citing works

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Pinotti, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01967 · Cited by 147 · see citing works

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J. C. S., Chia, S., Bernard, P. S., Nielsen, T. O., Ellis, M. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds080 · Cited by 141 · see citing works

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Mauriac, L., Keshaviah, A. P., Debled, M., Mouridsen, H. T., Forbes, J., Thurlimann, B. J. K., Paridaens, R., Monnier, A., Láng, I., Wardley, A. M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm001 · Cited by 137 · see citing works

The changing role of ER in endocrine resistance

Nardone, A., Angelis, C. D., Trivedi, M. V., Osborne, C. K., & Schiff, R. (2015) · The Breast · doi:10.1016/j.breast.2015.07.015 · Cited by 136 · see citing works

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Tang, G., Cuzick, J. M., Costantino, J. P., Dowsett, M., Forbes, J., Crager, M., Mamounas, E. P., Shak, S., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3714 · Cited by 135 · see citing works

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

Mamounas, E. P., Liu, Q., Paik, S., Baehner, F. L., Tang, G., Jeong, J., Kim, S. R., Butler, S. M., Jamshidian, F., Cherbavaz, D. B., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw259 · Cited by 129 · see citing works

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Ciruelos, E., Bellet, M., Pavesi, L., Lluch, A. M., Visini, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8675 · Cited by 127 · see citing works

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811714 · Cited by 126 · see citing works

Outcome of special types of luminal breast cancer

Colleoni, M. A., Rotmensz, N., Maisonneuve, P., Mastropasqua, M. G., Luini, A., Veronesi, P., Intra, M., Montagna, E., Cancello, G., Cardillo, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr461 · Cited by 123 · see citing works

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Ruhstaller, T., Giobbie‐Hurder, A., Colleoni, M. A., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00440 · Cited by 111 · see citing works

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Wagner, L. I., Gray, R. J., Sparano, J. A., Whelan, T. J., Garcia, S. F., Yanez, B. R., Tevaarwerk, A. J., Carlos, R. C., Albain, K. S., Olson, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01866 · Cited by 106 · see citing works

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Viale, G., Regan, M. M., Dell’Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G. M., Forbes, J., Paridaens, R., Colleoni, M. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq738 · Cited by 101 · see citing works

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Kashiwaba, M., Ohtani, S., Taira, N., Sakai, T., Hasegawa, Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4964-y · Cited by 101 · see citing works

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Prat, A., Galván, P., Jiménez, B., Buckingham, W., Jeiranian, H. A., Schaper, C., Vidal, M. J., Álvarez, M., Díaz, S., Ellis, C. E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0630 · Cited by 97 · see citing works

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Palmieri, C., Cleator, S. J., Kilburn, L., Kim, S.-B., Ahn, S. H., Beresford, M. J., Gong, G., Mansi, J., Mallon, E., Reed, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3183-4 · Cited by 96 · see citing works

Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

Bear, H. D., Wan, W., Robidoux, A., Rubin, P., Limentani, S. A., White, R. L., Granfortuna, J. M., Hopkins, J. O., Oldham, D. S., Rodriguez, A. A., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24610 · Cited by 96 · see citing works

Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases

Hoefnagel, L. D. C., Moelans, C. B., Meijer, S. L., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., et al. (2012) · Cancer · doi:10.1002/cncr.27518 · Cited by 93 · see citing works

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

Woodward, W. A., Barlow, W. E., Jagsi, R., Buchholz, T. A., Shak, S., Baehner, F. L., Whelan, T. J., Davidson, N. E., Ingle, J. N., King, T. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5559 · Cited by 79 · see citing works

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer

Poorvu, P. D., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Collins, L. C., Peppercorn, J. M., Schapira, L., Borges, V. F., Come, S. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01959 · Cited by 74 · see citing works

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario

Levine, M. N., Julian, J. A., Bedard, P. L., Eisen, A. F., Trudeau, M., Higgins, B. P., Bordeleau, L. J., & Pritchard, K. I. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8503 · Cited by 71 · see citing works

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer

Albanell, J., Svedman, C., Gligorov, J., Holt, S., Bertelli, G., Blohmer, J., Rouzier, R., Lluch, A. M., & EIERMANN, W. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.027 · Cited by 71 · see citing works

Management of Aromatase Inhibitor–Induced Musculoskeletal Symptoms

Gupta, A., Henry, N. L., & Loprinzi, C. L. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00113 · Cited by 70 · see citing works

Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?

Coates, A. S., Colleoni, M. A., & Goldhirsch, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7879 · Cited by 67 · see citing works

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

Tung, N., Robson, M. E., Ventz, S., Santa-Maria, C. A., Marcom, P. K., Nanda, R., Shah, P. D., Ballinger, T. J., Yang, E. S.-H., Melisko, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1002 · Cited by 60 · see citing works

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study

Noske, A., Möbus, V. J., Weber, K. E., Schmatloch, S., Weichert, W., Köhne, C., Solbach, C., Heppner, B. I., Steiger, K., Müller, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.010 · Cited by 48 · see citing works

Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy

Seah, D. S. E., Vaz-Luís, I., Macrae, E. R., Sohl, J. J., Litsas, G., Winer, E. P., Lin, N., & Burstein, H. J. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0008 · Cited by 47 · see citing works

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Dowsett, M., Lønning, P. E., & Davidson, N. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3728 · Cited by 38 · see citing works

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Gnant, M., Steger, G. G., Greil, R., Fitzal, F., Mlineritsch, B., Manfreda, D., Tausch, C., Balić, M., Dubsky, P. C., Moik, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs3-01 · Cited by 37 · see citing works

Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk

Dowsett, M., & Turner, N. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01412 · Cited by 33 · see citing works

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System

Weiss, A. C., King, T. A., Hunt, K. K., & Mittendorf, E. A. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2018.03.005 · Cited by 28 · see citing works

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Veer, L. V. ‘., Yau, C. S. F., Yu, N., Benz, C. C., Nordenskjöld, B. A., Fornander, T., Stål, O., Esserman, L. J., & Lindström, L. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4428-9 · Cited by 19 · see citing works

Management of Hormone Deprivation Symptoms After Cancer

Faubion, S. S., Loprinzi, C. L., & Ruddy, K. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.009 · Cited by 14 · see citing works

Pharmacogenomics and Endocrine Therapy in Breast Cancer

Hayes, D. F., & Rae, J. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.03119 · Cited by 13 · see citing works

Breast Cancer Statistics, 2022

Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A. K., Jemal, A., & Siegel, R. L. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,376 · see citing works

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W., Poortmans, P., Regan, M. M., Senn, H.-J., Winer, E. P., Gnant, M. I., Aebi, S. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 850 · see citing works

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777 · see citing works

Deciphering breast cancer: from biology to the clinic

Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 761 · see citing works

Protein degraders enter the clinic — a new approach to cancer therapy

Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Epigenetic mechanisms in breast cancer therapy and resistance

Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 466 · see citing works

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V. G., Aft, R., Agnese, D. M., Allison, K. H., Anderson, B. M., Burstein, H. J., Chew, H. K., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 463 · see citing works

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Bidard, F., Bessard, A. C. H., Dalenc, F., Bachelot, T., Pierga, J., Rouge, T. D. L. M., Sabatier, R., Dubot, C., Frenel, J., Ferrero, J. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00555-1 · Cited by 361 · see citing works

A Comprehensive Review of HER2 in Cancer Biology and Therapeutics

Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 258 · see citing works

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Curigliano, G., Burstein, H. J., Gnant, M., Loibl, S., Cameron, D., Regan, M. M., Denkert, C., Poortmans, P. M., Weber, W. P., Thurlimann, B. J. K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.017 · Cited by 245 · see citing works

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02554 · Cited by 235 · see citing works

Therapeutic resistance to anti-oestrogen therapy in breast cancer

Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 180 · see citing works

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-066381 · Cited by 170 · see citing works

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil‐Ressler, S., Balić, M., Heck, D., Jakesz, R., Thaler, J., Egle, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104162 · Cited by 161 · see citing works

Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance

Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 149 · see citing works

Nanoparticle-based materials in anticancer drug delivery: Current and future prospects

Ajith, S., AlMomani, F. A., Elhissi, A. M. A., & Husseini, G. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21227 · Cited by 121 · see citing works

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Bardia, A., Cortés, J., Bidard, F., Neven, P., García-Sáenz, J. Á., Aftimos, P. G., O’Shaughnessy, J., Lu, J. M., Tonini, G., Scartoni, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1073 · Cited by 121 · see citing works

Molecular classification of hormone receptor-positive HER2-negative breast cancer

Jin, X., Zhou, Y.-F., Ma, D., Zhao, S., Lin, C., Xiao, Y., Fu, T., Liu, C., Chen, Y., Xiao, W.-X., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01507-7 · Cited by 117 · see citing works

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

Lindeman, G. J., Fernando, T. M., Bowen, R. L., Jerzak, K. J., Song, X., Decker, T. W., Boyle, F. M., McCune, S., Armstrong, A. C., Shannon, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3811 · Cited by 98 · see citing works

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 92 · see citing works

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Martín, M., Lim, E., Chávez‐MacGregor, M., Bardia, A., Wu, J., Zhang, Q., Nowecki, Z. I., Cruz, F. J. S. M., Нурисламович, С. Р., Kim, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01500 · Cited by 83 · see citing works

ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing

Venetis, K., Pepe, F., Pescia, C., Cursano, G., Criscitiello, C., Frascarelli, C., Mane, E., Russo, G., Salimbeni, B. T., Troncone, G., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102642 · Cited by 68 · see citing works

Endoplasmic reticulum stress targeted therapy for breast cancer

Xu, D., Liu, Z., Liang, M., Fei, Y., Zhang, W., Wu, Y., & Tang, J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00964-7 · Cited by 67 · see citing works

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer

Zheng, Z., Xia, L., Hu, G.-S., Liu, J., Hu, Y.-H., Chen, Y.-J., Jia-yin, P., Zhang, W., & Liu, W. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac778 · Cited by 63 · see citing works

Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction

Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Cheng, Y., & Liao, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01041-w · Cited by 61 · see citing works

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57 · see citing works

Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor

Gu, J., Zhu, N., Li, H., Zhao, T., Zhang, C., Liao, D.-F., & Li, Q. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00694-5 · Cited by 57 · see citing works

16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer

Ulaner, G. A. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.002 · Cited by 51 · see citing works

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

Palmieri, C., Linden, H. M., Birrell, S. N., Wheelwright, S. J., Lim, E., Schwartzberg, L. S., Dwyer, A. R., Hickey, T. E., Rugo, H. S., Cobb, P. W., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00004-4 · Cited by 50 · see citing works

Sex hormones, the anticancer immune response, and therapeutic opportunities

Conforti, F., Pala, L., Mitri, D. D., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., Locatelli, M., Facella, F., Pas, T. M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.013 · Cited by 48 · see citing works

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer

Conforti, F., Pala, L., Bagnardi, V., Pas, T. M. D., Colleoni, M. A., Buyse, M. E., Hortobágyi, G. N., Gianni, L., Winer, E. P., Loibl, S., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3755 · Cited by 44 · see citing works

Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer

Zhou, J., Cheng-hao, Y., & Cheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.824531 · Cited by 45 · see citing works

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Lauro, V. D., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Mastro, L. D., Giuliano, M., Puglisi, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100629 · Cited by 43 · see citing works

“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”

Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 46 · see citing works

Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics

Amato, O., Guarneri, V., & Girardi, F. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000991 · Cited by 40 · see citing works

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Delaloge, S., Dureau, S., D’Hondt, V., Desmoulins, I., Heudel, P., Duhoux, F. P., Lévy, C., Lerebours, F., Mouret‐Reynier, M., Dalenc, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.014 · Cited by 39 · see citing works

Robust ERα-Targeted Near-Infrared Fluorescence Probe for Selective Hydrazine Imaging in Breast Cancer

Tang, C. C., Tong, H., Liu, B., Wang, X., Jin, Y., Tian, E., & Wang, F. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03395 · Cited by 39 · see citing works

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Cao, L.-Q., Sun, H., Xie, Y., Patel, H. H., Bo, L., Lin, H., & Chen, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1340764 · Cited by 37 · see citing works

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

Massa, D., Vernieri, C., Nicolè, L., Criscitiello, C., Boissière‐Michot, F., Guiu, S., Bobrie, A., Griguolo, G., Miglietta, F., Vingiani, A., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae178 · Cited by 37 · see citing works

Updates in endocrine therapy for metastatic breast cancer

Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 34 · see citing works

Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis

Su, F., Yang, X., Yin, J., Shen, Y., & Tan, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13778-9 · Cited by 33 · see citing works

Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer

Ring, A., Spataro, M., WICKI, A. N., & Aceto, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.929893 · Cited by 32 · see citing works

The role of estrogen receptors in intracellular estrogen signaling pathways, an overview

Gui, Z., Shi, W., Zhou, F., Yan, Y., Li, Y., & Xu, Y. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106632 · Cited by 34 · see citing works

Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside

Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 30 · see citing works

First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis

Karimaa, M., Riikonen, R., Kettunen, H., Taavitsainen, P., Ramela, M., Chruściel, M., Karlsson, S., Rummakko, P., Simola, O., Wohlfahrt, G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0115 · Cited by 31 · see citing works

GRPR-targeting radiotheranostics for breast cancer management

D’Onofrio, A., Engelbrecht, S., Läppchen, T., Rominger, A., & Gourni, E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1250799 · Cited by 29 · see citing works

A Coagulation-Related Gene-Based Prognostic Model for Invasive Ductal Carcinoma

Li, J., Du, J., Wang, Y., & Jia, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.722992 · Cited by 28 · see citing works

Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics

Cen, Y., Chen, L., Liu, Z., Lin, Q., Fang, X., Yao, H., & Gong, C. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01352-x · Cited by 27 · see citing works

How we Treat HR-Positive, HER2-Negative Early Breast Cancer

López‐Tarruella, S., Echavarría, I., Jerez, Y., Herrero, B., Casado, S. G., & Martín, M. (2022) · Future Oncology · doi:10.2217/fon-2021-0668 · Cited by 26 · see citing works

Charge Conversion Polymer–Liposome Complexes to Overcome the Limitations of Cationic Liposomes in Mitochondrial-Targeting Drug Delivery

Shueng, P., Yu, L.-Y., Hou, H.-H., Chiu, H., & Lo, C.-L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063080 · Cited by 26 · see citing works

The mevalonate pathway in breast cancer biology

Göbel, A., Riffel, R. M., Hofbauer, L. C., & Rachner, T. D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215761 · Cited by 25 · see citing works

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

Filipits, M., Rudas, M., Singer, C. F., Fitzal, F., Bagó-Horváth, Z., Greil, R., Balić, M., Lax, S., Halper, S., Hulla, W., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100228 · Cited by 25 · see citing works

The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer

Chiang, C., Yang, H., Zhu, L., Chen, C., Chen, C., Zuo, Y., & Zheng, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918509 · Cited by 25 · see citing works

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility

Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 25 · see citing works

How I treat endocrine-dependent metastatic breast cancer

Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 25 · see citing works

Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence

Huang, J., Zhang, J., Ang, L., Li, M., Zhao, M., Wang, Y., & Wu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1265520 · Cited by 24 · see citing works

Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer

Eustace, A. J., Lee, M. J., Colley, G., Roban, J., Downing, T., & Buchanan, P. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.41 · Cited by 23 · see citing works

Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β

Murakami-Nishimagi, Y., Sugimoto, K., Kobayashi, M., Tachibana, K., Kojima, M., Okano, M., Hashimoto, Y., Saji, S., Ohtake, T., & Chiba, H. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01646-z · Cited by 23 · see citing works

Circulating tumor DNA: from discovery to clinical application in breast cancer

Xu, J., Gao, H., Guan, X., Meng, J., Ding, S., Qian, L., & Yi, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355887 · Cited by 23 · see citing works

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23 · see citing works

A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer

Harbeck, N., Burstein, H. J., Hurvitz, S. A., Johnston, S. R. D., & Vidal, G. A. (2022) · Cancer · doi:10.1002/cncr.34161 · Cited by 20 · see citing works

Phytoestrogens, novel dietary supplements for breast cancer

Huang, S., Qi, B., Yang, L., Wang, X., Huang, J., Zhao, Y., Hu, Y., & Xiao, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114341 · Cited by 20 · see citing works

Mechanisms of Traditional Chinese medicine/natural medicine in HR-positive Breast Cancer: A comprehensive Literature Review

Yu, Q., Xu, C., Song, J., Jin, Y., & Gao, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117322 · Cited by 20 · see citing works

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy

Wang, L., Luo, R., Lu, Q., Jiang, K., Hong, R., Lee, K., Zhang, P., Zhou, D., Wang, S., & Xu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735670 · Cited by 19 · see citing works

Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development

Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101239 · Cited by 19 · see citing works

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Copur, M. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101282 · Cited by 19 · see citing works

Oncotype DX Recurrence Score in premenopausal women

Zhang, S., Fitzsimmons, K. C., & Hurvitz, S. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081077 · Cited by 18 · see citing works

The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?

da Luz, F. A. C., Araújo, B. J., & de Araújo, R. A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103781 · Cited by 18 · see citing works

Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer

Xie, T., Zahid, H., Ali, A. R., Joyce, R., Yang, G., Winz, C., Le, Y., Zhou, R., Furmanski, P., Hu, L., et al. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116375 · Cited by 18 · see citing works

Metastasis prevention: targeting causes and roots

Schegoleva, A. A., Khozyainova, A. A., Gerashchenko, T. S., Zhuikova, L. D., & Denisov, E. V. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10162-x · Cited by 18 · see citing works

Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer

Ruscitto, F., Roda, N., Priami, C., Migliaccio, E., & Pelicci, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116271 · Cited by 18 · see citing works

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations

Bielo, L. B., Rocco, E. G., Trapani, D., Zagami, P., Salimbeni, B. T., Esposito, A., Belli, C., Crimini, E., Venetis, K., Munzone, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103731 · Cited by 17 · see citing works

A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2− Breast Cancer

Ben-Yaakov, H., Meshel, T., Pasmanik, M., Körner, C., & Ben‐Baruch, A. (2023) · Cancers · doi:10.3390/cancers15082255 · Cited by 17 · see citing works

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models

Zhou, F., Yang, G., Xue, L., Liu, Y., Guo, Y., Zhu, J. Y., Yuan, L., Gu, P., Tang, F., Shan, J., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01695-4 · Cited by 17 · see citing works

ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

Betz, M., Massard, V., Gilson, P., Witz, A., Dardare, J., Harlé, A., & Merlin, J. (2023) · Cancers · doi:10.3390/cancers15215169 · Cited by 17 · see citing works

Aromatase Inhibitor Therapy Increases the Risk of New-Onset Atrial Fibrillation in Patients With Breast Cancer

Ho, I., Wong, C., Wong, Y., Lam, T.-H., Leung, I. S. H., Lin, M., Lui, D. T. W., Kwok, W. C., Tam, C. C., Chan, Y., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.09.014 · Cited by 17 · see citing works

Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study

Kim, J. H. (2024) · Cancers · doi:10.3390/cancers16162869 · Cited by 17 · see citing works

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Tarantino, P., Burstein, H. J., Lin, N., Krop, I. E., Winer, E. P., Schnitt, S. J., Hamilton, E. P., Hurvitz, S. A., Rugo, H. S., Curigliano, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.004 · Cited by 17 · see citing works

Development of novel agents for the treatment of early estrogen receptor positive breast cancer

Elliott, M. J., & Cescon, D. W. (2021) · The Breast · doi:10.1016/j.breast.2021.11.007 · Cited by 15 · see citing works

Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway

Liu, C., Li, S., Zhang, X., Jin, C., Zhao, B., Li, L., Miao, Q., Jin, Y. H., & Fan, Z. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00542-6 · Cited by 15 · see citing works

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer

Giacomini, A., Turati, M., Grillo, E., Rezzola, S., Ghedini, G. C., Schuind, A. C., Foglio, E., Maccarinelli, F., Faletti, J., Filiberti, S., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00441-y · Cited by 15 · see citing works

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer

Mamann, A., Pradat, Y., Bidard, F., Delaloge, S., Cabel, L., Faull, I., Marques, S., Bachelot, T., Dalenc, F., Rouge, T. D. L. M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.06.015 · Cited by 14 · see citing works

Real-World Outcomes of Elacestrant in ER+, HER2−, ESR1 -Mutant Metastatic Breast Cancer

Rugo, H. S., Kaklamani, V., McArthur, H. L., Wander, S. A., Gradishar, W. J., Mahtani, R. L., Pegram, M. D., Lustberg, M. B., Swallow, E., Maitland, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3040 · Cited by 14 · see citing works

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

Bergqvist, M., Nordmark, A., Williams, A., Paoletti, C., Barlow, W. E., Cobain, E. F., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., et al. (2023) · Biomarkers · doi:10.1080/1354750x.2023.2168063 · Cited by 14 · see citing works

Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes

Xie, J., Ding, Y., Li, X., Pu, R., Liu, W., Li, P., & Yin, J. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28510 · Cited by 14 · see citing works

Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs

Watson, J., Wang, T., Ho, K.-L., Yuan, F., Mahawan, T., Dobbin, K. K., & Zhao, S. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01705-5 · Cited by 14 · see citing works

Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer

Lin, Y., Gao, H., Li, H., Hu, Q., Du, B., Li, S., Xu, F., Cheng, M., Zou, J., Zheng, X., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34945 · Cited by 15 · see citing works

Safety of solid oncology drugs in older patients: a narrative review

Rousseau, A., Géraud, A., Geiss, R., Farcet, A., Spano, J., Hamy, A., & Gougis, P. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103965 · Cited by 14 · see citing works

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel

Arboleda-Osorio, B., Bartsch, R., de Azambuja, E., Hamilton, E. P., Harbeck, N., Klemp, J. R., Knauer, M., Küemmel, S., Mahtani, R. L., Schwartzberg, L. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac101 · Cited by 14 · see citing works

Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy

Burgermeister, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713661 · Cited by 13 · see citing works

Invasive papillary carcinoma of the breast

Wang, S., Zhang, Q., & Mao, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374091 · Cited by 13 · see citing works

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Li, J., Zhao, B., Zhu, Y.-Q., & Wu, J. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/5132916 · Cited by 13 · see citing works

Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer

de Oliveira-Lopes, A. F., Götze, M. M., Lopes-Neto, B. E., Guerreiro, D. D., Bustamante‐Filho, I. C., & Moura, A. A. (2024) · Veterinary and Comparative Oncology · doi:10.1111/vco.12996 · Cited by 13 · see citing works

Estrogen Receptor-α Exacerbates EGF-Inducing Airway Remodeling and Mucus Production in Bronchial Epithelium of Asthmatics

Qin, L., Yue, J., Guo, M., Zhang, C., Fang, X., Zhang, S., Bai, W., Liu, X., & Xie, M. (2023) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2023.15.5.614 · Cited by 12 · see citing works

Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives

Ndlovu, H., Lawal, I. O., Mokoala, K. M. G., & Sathekge, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031575 · Cited by 12 · see citing works

Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer

McGrath, M. K., Abolhassani, A., Guy, L., Elshazly, A. M., Barrett, J. T., Mivechi, N. F., Gewirtz, D. A., & Schoenlein, P. V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1298423 · Cited by 12 · see citing works

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Xu, B., Zhang, Q., Luo, Y., Tong, Z., Sun, T., Shan, C., Liu, X., Yao, Y., Zhao, B., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56096-2 · Cited by 14 · see citing works

Opportunities, obstacles and current challenges of flavonoids for luminal and triple-negative breast cancer therapy

Vachetta, V. S., Marder, M., Troncoso, M. F., & Elola, M. T. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100077 · Cited by 12 · see citing works

288 Changes in Estrogen Receptor (ER), Progesterone Receptor (PgR) and HER2/neu Status During Primary Systemic Chemotherapy in Breast Cancer

Tozuka, K., Horiguchi, J., Takata, D., Rokutanda, N., Nagaoka, R., TOKINIWA, H., Kikuchi, M., Satou, A., & Takeyoshi, I. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70355-6

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 178 · see citing works

Systemic Therapy of Breast Cancer

Margolese, R. G., Hortobágyi, G. N., & Buchholz, T. A. (2003)

P296 Current patterns and long-time trends in the adjuvant systemic therapy of breast cancer in Grodno region (Belarus)

Казакевич, Д. В., Miklashevich, F., Myshko, I., Solodovnikov, A. G., & Вдовиченко, В. П. (2011) · The Breast · doi:10.1016/s0960-9776(11)70238-7

ER-positive HER2-negative breast cancer

(2016)